SEARCH:   Advanced

Blood, 30 April 2009, Vol. 113, No. 18, pp. 4179-4187. Prepublished online as a Blood First Edition Paper on November 13, 2008; DOI 10.1182/blood-2008-07-172007. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-07-172007v1 113/18/4179    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Juliusson, G. Articles by Höglund, M. Search for Related Content PubMed PubMed Citation Articles by Juliusson, G. Articles by Höglund, M. Related Collections Free Research Articles Myeloid Neoplasia Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Gunnar Juliusson1,9, Petar Antunovic2,9, Åsa Derolf3,9, Sören Lehmann4,9, Lars Möllgård4,9, Dick Stockelberg5,9, Ulf Tidefelt6,9, Anders Wahlin7,9, and Martin Höglund8,9 1 Department of Hematology and Regional Tumor Registry, Lund University Hospital, Lund; 2 Department of Hematology and Regional Tumor Registry, Linköping University Hospital, Linköping; 3 Center of Hematology and Regional Tumor Registry, Karolinska University Hospital, Stockholm; 4 Department of Hematology, Karolinska University Hospital, Huddinge; 5 Department of Medicine and Regional Tumor Registry, Sahlgrenska University Hospital, Göteborg; 6 Department of Medicine, Örebro University Hospital, Örebro; 7 Department of Medicine and Regional Tumor Registry, Norrland University Hospital, Umeå; 8 Department of Hematology and Regional Tumor Registry, Academic Hospital, Uppsala, Sweden; and 9 Swedish Acute Myeloid Leukemia Registry Group Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit for intensive treatment because of the risk of fatal toxicity. The Swedish Acute Leukemia Registry covers 98% of all patients with AML (nonacute promyelocytic leukemia) diagnosed in 1997 to 2005 (n = 2767), with a median follow-up of 5 years, and reports eligibility for intensive therapy, performance status (PS), complete remission rates, and survival. Outcomes were strongly age and PS dependent. Early death rates were always lower with intensive therapy than with palliation only. Long-term survivors were found among elderly given intensive treatment despite poor initial PS. Total survival of elderly AML patients was better in the geographic regions where most of them were given standard intensive therapy. This analysis provides unique real world data from a large, complete, and unselected AML population, both treated and untreated, and gives background to treatment decisions for the elderly. Standard intensive treatment improves early death rates and long-term survival compared with palliation. Most AML patients up to 80 years of age should be considered fit for intensive therapy, and new therapies must be compared with standard induction. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Closer to the truth in AML Jacob M. Rowe Blood 2009 113: 4129-4130. [Full Text] [PDF] This article has been cited by other articles: J. M. Rowe Closer to the truth in AML Blood, April 30, 2009; 113(18): 4129 - 4130. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020